← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,516	+56	+2%	$161B
2	2 Danaher DHR $158B	2,150	-26	-1%	$111B
3	3 Novartis NVS $279B	1,405	+19	+1%	$17.2B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,246	+43	+4%	$49B
5	5 Agilent Technologies A $49.1B	1,043	+33	+3%	$32.2B
6	6 Alnylam Pharmaceuticals ALNY $30B	823	+168	+26%	$59.2B
7	7 Illumina ILMN $41B	778	+39	+5%	$14.9B
8	8 Charles River Laboratories CRL $14.4B	556	+37	+7%	$7.92B
9	9 Revvity RVTY $17B	524	-16	-3%	$10.1B
10	10 CRISPR Therapeutics CRSP $4.86B	441	+7	+2%	$4.68B
11	11 Ionis Pharmaceuticals IONS $7.1B	436	+74	+20%	$11B
12	12 Guardant Health GH $21.9B	395	+30	+8%	$7.65B
13	13 BridgeBio Pharma BBIO $12.7B	392	+33	+9%	$9.62B
14	14 GRAIL Inc GRAL $6.24B	348	+4	+1%	$1.47B
15	15 Bruker BRKR $8.47B	340	-30	-8%	$4.31B
16	16 Qiagen QGEN $9.41B	340	+21	+7%	$6.84B
17	17 Sarepta Therapeutics SRPT $1.78B	320	-43	-12%	$1.67B
18	18 10x Genomics TXG $9.52B	317	+20	+7%	$1.44B
19	19 Arrowhead Research ARWR $8.25B	304	+22	+8%	$3.83B
20	20 Ultragenyx Pharmaceutical RARE $1.47B	303	-7	-2%	$2.87B
21	21 Veracyte VCYT $3.5B	298	+20	+7%	$3.08B
22	22 PTC Therapeutics PTCT $4.98B	294	+10	+4%	$5.07B
23	23 Krystal Biotech KRYS $9.79B	284	+9	+3%	$4.94B
24	24 Intellia Therapeutics NTLA $1.6B	284	+2	+0.7%	$1.8B
25	25 Azenta AZTA $1.63B	277	-1	-0.4%	$1.44B